Partners

We are currently collaborating with Sinovant, a wholy-owned subsidiary of Roivant, for the development of derazantinib (ARQ 087), a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China. Roivant is dedicated to the development and commercialization of novel therapies for the treatment of diseases with high unmet need. The People’s Republic of China has one of the highest incidences of intrahepatic cholangiocarcinoma (iCCA), a devastating form of biliary tract cancer. We are currently conducting a registrational trial with derazantinib in the U.S. and Europe for the treatment of patients with FGFR2 fusion iCCA. In this collaboration, we have granted a subsidiary of Roivant an exclusive license to develop and commercialize derazantinib in the People’s Republic of China, Hong Kong, Macau and Taiwan. This collaboration will help to further the development of derazantinib for the treatment of iCCA in Greater China, as well as for the treatment of other tumor types with high rates of FGFR mutation.

We are currently collaborating with Basilea Pharmaceutica Ltd. (SIX: BSLN) for the research, development, manufacture and commercialization of derazantinib (ARQ 087), a pan-FGFR (fibroblast growth factor receptor) inhibitor, worldwide, excluding the People’s Republic of China, Hong Kong, Macau and Taiwan. Basilea is dedicated to developing therapies to address resistance and non-response to current treatments across multiple therapeutic areas, including cancer. We are currently conducting a registrational trial with derazantinib in the U.S. and Europe for the treatment of patients with FGFR2 fusion intrahepatic cholangiocarcinoma (iCCA), a devastating form of biliary tract cancer. Current treatments for patients with iCCA are limited, with no therapies approved globally for this disease. This collaboration will continue the development of derazantinib in iCCA and other tumor types with FGFR dysregulation.

Sinovant Sciences
Basilea Pharmaceutica Ltd.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300